Predict your next investment

HEALTHCARE | Disease Diagnosis
viomics.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$250K

About Viomics

Viomics is a molecular diagnostics company that uses scientific, engineering and business strategies to discover, develop and deliver paradigm-changing cancer detection applications to enable early intervention that cures previously deadly cancers.On March 3rd, 2020, Viomics was acquired by Exact Sciences. Terms of the transaction were not disclosed.

Viomics Headquarter Location

445 N 5th Street

Phoenix, Arizona, 85004,

United States

Latest Viomics News

Phoenix Based Paradigm And Viomics Acquired by Exact Sciences

Mar 6, 2020

On March 3, 2020, Exact Sciences Corp. ( NASDAQ: EXAS ) announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two privately held companies based in Phoenix. Together, Paradigm and Viomics provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery, extending Exact Sciences’ lab testing and research and development capabilities. “The addition of these companies and their talented team members to Exact Sciences is another step forward in extending our leadership in advanced cancer diagnostics,” said Kevin Conroy, chairman and CEO of Exact Sciences. “Viomics’ research capabilities and the Paradigm therapy selection test and scalable clinical lab, combined with the powerful Exact Sciences commercial platform, allow us to provide patients with smarter, faster answers throughout the cancer continuum.” Paradigm currently offers a comprehensive genomic profiling test for patients with advanced, refractory, or recurrent cancer, allowing physicians to better understand a patient’s tumor profile and more effectively recommend targeted therapies or clinical trials. Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies under its MolDx program, recently covered the test under its existing local coverage determination for Next-Generation Sequencing for Solid Tumors. Differentiated from other tests by a design that requires smaller sample requirements and delivers faster results, the test is critical in supporting treatment decisions and builds upon the successful foundation of the Exact Sciences’ Precision Oncology team. Viomics provides extensive sequencing capabilities and expertise in identifying unique biomarkers that indicate the presence of cancer in solid tissue and blood. The expertise of their team brings additional resources to Exact Sciences’ world-class research and development team, and any future biomarker discoveries may be used in Exact Sciences’ pipeline cancer tests. Sequencing will play a pivotal role in bringing tissue and blood-based advanced cancer diagnostics to patients and physicians. Viomics was founded by David Mallery and Scott Morris, chief scientific officer. The company is a past winner of Arizona State University’s  Edson Student Entrepreneur Initiative , a startup accelerator that provides funding, office space, mentorship and training to student entrepreneurs from all university disciplines. ( Source: ASU ) According to the Exact Sciences press release, Paradigm and Viomics will remain based in Phoenix. Financial terms of the transactions are not being disclosed. XMS Capital Partners served as advisor to Exact Sciences on these transactions. A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Alongside its visionary collaborators and in partnership with communities, Exact Sciences unites the best resources to help advance the fight against cancer. According to the press release, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Based in Madison, Wisconsin, Exact Sciences’ portfolio of tests includes Cologuard which was approved by the FDA in August 2014 and  the Oncotype DX portfolio of breast, colon and prostate cancer tests which apply advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions, helping to guide treatment decisions for more than 1 million cancer patients worldwide and which were originally developed by Genomic Health, Inc. Exact Sciences acquired Genomic Health in 2019 via a cash and stock transaction valued at $2.8 billion. For more information on the acquisition of Paradigm and Viomics, visit:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Viomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Viomics is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Viomics Patents

Viomics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2013

8/23/2016

Oncology, Hematology, Anatomical pathology, Cancer treatments, Transcription factors

Grant

Application Date

1/4/2013

Grant Date

8/23/2016

Title

Related Topics

Oncology, Hematology, Anatomical pathology, Cancer treatments, Transcription factors

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.